KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Shares Outstanding for 13 consecutive years, with $80.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.7% to $80.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.0 million through Dec 2025, up 4.7% year-over-year, with the annual reading at $80.0 million for FY2025, 4.7% up from the prior year.
  • Shares Outstanding for Q4 2025 was $80.0 million at Xenon Pharmaceuticals, up from $77.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $80.0 million in Q4 2025, with the low at $1.0 million in Q2 2021.
  • Average Shares Outstanding over 5 years is $60.8 million, with a median of $64.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding crashed 97.1% in 2021, then soared 6055.76% in 2022.
  • Over 5 years, Shares Outstanding stood at $51.6 million in 2021, then grew by 21.21% to $62.6 million in 2022, then grew by 20.42% to $75.4 million in 2023, then increased by 1.39% to $76.4 million in 2024, then rose by 4.7% to $80.0 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $80.0 million, $77.1 million, and $76.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.